Video: What Patients Want and Are Willing to Risk with SLE Dr. Kathryn Dao discusses abstract POS0086 at #EULAR2022 which looks at real life lupus patient preferences who are willing to undergo risk in order to get the treatment outcome that they desire. https://t.co/kHZz5MrZi2 https://t.co/XRsoXHR1ce

• https://bit.ly/3NiaNlu

WIN-Lupus is no winner. Stopping #MMF or #Azathioprine after 2 to 3 yrs of well controlled #SLE is a loser due to more #lupus nephritis. Diff from RCT of MMF taper in remission pts. @RheumNow @eular_org #EULAR2022 https://t.co/Ut8uRonrNP

• Richard Conway on Twitter: "WIN-Lupus. RCT of stopping treatment in SLE. A…

So what diet to follow with autoimmunity in mind? So many, all with different instructions. Let’s concentrate on where they agree: yes to fruits & vegetables no to emulsifiers & processed foods #EULAR2022 @RheumNow https://t.co/I9abweQOyZ

#OP0279 #EULAR2022 Let's start with N=5! Promising new therapy CAR T-cell in #lupus. All patients were refractory to various therapies and had active nephritis. Post-treatment, all responded clinically and serologically! Need to go to RCT next @RheumNow https://t.co/RaTlVALQqn

Watch: AURORA-2 Two-year Results Voclosporin For Lupus Nephritis https://t.co/k61KOBXRSl #EULAR2022 https://t.co/Q7cjqvQyFG

• https://bit.ly/3Md48b4

Pharmacodynamic effect of sequential #belimumab and #rituximab therapy in patients with systemic #lupus: BLISS-BELIEVE study #EULAR2022 >CR https://t.co/AgBBuqYatW

WIN-Lupus. RCT of stopping treatment in SLE. All on HCQ. Randomised to stop Aza/MMF after being stable on for 2-3 years. Relapse proliferative nephritis in 25% vs 10%. Severe SLE flare 32% vs 13%. @RheumNow #EULAR2022 OP0280 https://t.co/IAcCoKw1YI

• EULAR Abstract Archive